Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3374054 | 0.82 | HCAR2 (0.42) | HDAC6 | |
| SCHEMBL31003402 | 0.81 | SCN2B (0.35) | HDAC6 | |
| SCHEMBL31003355 | 0.80 | MAPK1 (0.41) | — | |
| SCHEMBL3372466 | 0.80 | MAPK1 (0.41) | — | |
| SCHEMBL24214090 | 0.76 | CYP11B1 (0.41) | — | |
| SCHEMBL23166462 | 0.75 | HDAC6 (0.46) | HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL27188809 | 0.74 | MAPK14 (0.37) | HDAC1 | |
| SCHEMBL29896108 | 0.74 | MAPK14 (0.37) | HDAC1 | |
| SCHEMBL21628554 | 0.74 | HDAC6 (0.45) | HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL23167323 | 0.73 | HDAC6 (0.59) | HDAC6HDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381148-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | TENAYA THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230381148-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | TENAYA THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230123856-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230123856-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4037670-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | Tenaya Therapeutics, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| WO-2021067859-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021067859-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381148-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | HDAC6, HDAC1, HDAC2 | HDAC6 1/4885HDAC1 2/4885HDAC3 4/4885 |
| US-20230123856-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | SLC28A1, SLC5A1, SLC9A5 | HDAC6 40/4885HDAC1 60/4885HDAC3 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.